Article

A novel triple-action inhibitor targeting B-cell receptor signaling and BRD4 demonstrates preclinical activity in chronic lymphocytic leukemia

2022-05-11

Abstract excerpt

B-cell chronic lymphocytic leukemia (CLL) results from intrinsic genetic defects and complex microenvironment stimuli that fuel CLL cell growth through an array of survival-signaling pathways. Novel small-molecule agents targeting the B-cell receptor pathway and anti-apoptotic proteins alone or in combination have revolutionized the management of CLL, yet combination therapy carries significant toxicity and CLL st...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ace6db82-abd4-57d5-96a5-155d67635984
DOI: 10.1101/2022.05.11.491547

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A novel triple-action inhibitor targeting B-cell receptor signaling and BRD4 demonstrates preclinical activity in chronic lymphocytic leukemiaDOI 10.1101/2022.05.11.491547Read

Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies.Semantic proximity Read

Emerging Therapies in CLL in the Era of Precision MedicineSemantic proximity Read

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET InhibitorSemantic proximity Read

Chronic lymphocytic leukemia: biology, disease progression, and current treatment strategies.Semantic proximity Read

Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma modelsSemantic proximity Read

Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in Preclinical ModelsSemantic proximity Read

Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.Semantic proximity Read

Regulation of B Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell LymphomasSemantic proximity Read

The B-cell receptor signaling pathway as a therapeutic target in CLLSemantic proximity Read

Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphomaSemantic proximity Read

Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effectsSemantic proximity Read

Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations.Semantic proximity Read